Monzr M. Al Malki - Concepedia

Author

Monzr M. Al Malki

City Of Hope National Medical Center ORCID

Also Known As

Guido Marcucci, M Al-Malki, M Malki, M. Monzr Al-Malki, M.M. Al-Malki, Mazen AlMalki, Mohamed MALKI, Monzr M. Al Malki, Monzr Al Malki, Monzr Al-Malki

371

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

City Of Hope National Medical Center City of Hope The University of Texas MD Anderson Cancer Center Moffitt Cancer Center The Ohio State University

About

Monzr M. Al Malki is an author at City Of Hope National Medical Center specializing in hematology, medicine, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	26	1.4K
2	Health Sciences	10	10	439
3	Public Health	1	1	22
4	Allergy	1	1	54
5	Biomedical Engineering	1	1	321

Monzr M. Al Malki

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis Javier Bolaños‐Meade, Mehdi Hamadani, Juan Wu, New England Journal of Medicine	2023	460
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide Asad Bashey, Mei-Jie Zhang, Shannon R. McCurdy, Journal of Clinical Oncology ImmunologyBiomedical EngineeringImmunotherapyRegenerative MedicineTranslational Medicine	2017	321
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results David A. Sallman, Adam S. Asch, Monzr M. Al Malki, Blood	2019	216
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis Mahasweta Gooptu, Rizwan Romee, Andrew St. Martin, Blood	2021	157
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Journal of Clinical Oncology	2023	148
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL Peter Dreger, Anna Sureda, Kwang Woo Ahn, Blood Advances TransplantationMarrow TransplantationOncologyPtcy-based Haploidentical VsMalignant Blood Disorder	2019	112
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results Naval Daver, Paresh Vyas, Suman Kambhampati, Journal of Clinical Oncology	2023	110
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia Anthony S. Stein, Joycelynne Palmer, Ni‐Chun Tsai, Biology of Blood and Marrow Transplantation Hematological MalignancyCell TherapyTransplantationMarrow TransplantationRadiation Therapy	2017	95
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide Shannon R. McCurdy, Mei-Jie Zhang, Andrew St. Martin, Blood Advances	2018	92
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT Bhagirathbhai Dholaria, Bipin N. Savani, Myriam Labopin, Haematologica Cell TherapyTransplantationMarrow TransplantationConsensus RecommendationsStem Cell Transplantation	2019	84

Page 1